Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Rgnx save search
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2023-11-03 (Crawled : 23:00) - prnewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 altitude year one positive treatment trial diabetic
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 1.68%
H: 3.7%
C: 0.91%
rgx-202 fda candidate treatment designation duchenne therapy fast track designation
Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -1.43%
H: 0.98%
C: -0.37%
rgx-111 treatment trial positive
Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM
Published: 2023-02-22 (Crawled : 20:00) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.72%
H: 0.47%
C: -2.78%
rgx-121 treatment trial positive
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.45%
H: 2.13%
C: 0.22%
rgx-111 treatment trial mps-ih mps-i
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -3.01%
H: 0.77%
C: -10.46%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.74%
H: 11.76%
C: 7.35%
rgx-314 altitude treatment expansion trial positive diabetic
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy
Published: 2022-10-27 (Crawled : 12:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 1.18%
H: 1.81%
C: -2.24%
rgx-314 altitude treatment conference trial financial diabetic
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Published: 2022-10-03 (Crawled : 13:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 2.16%
H: 0.3%
C: -10.48%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.88%
H: 5.26%
C: 5.26%
rgx-314 treatment trials positive
Macular Degeneration Treatment Global Market to Reach $10.65 Billion by 2026 at a CAGR of 7.15%
Published: 2022-09-14 (Crawled : 10:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.98%
H: 7.63%
C: 2.67%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.55%
H: 0.42%
C: -0.72%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.41%
C: -0.76%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.41%
H: 11.64%
C: 6.22%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.38%
H: 2.53%
C: 1.48%
treatment global macular market
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
Published: 2022-08-31 (Crawled : 18:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 2.64%
H: 0.8%
C: -3.81%
rgx-121 treatment symposium trial positive study mps-ih
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 3.4%
H: 6.37%
C: 3.34%
rgx-121 treatment application license approval mps-ih
Global Macular Degeneration Treatment Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2022-06-09 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.49%
H: 0.47%
C: -1.59%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.89%
H: 0.67%
C: -6.05%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.75%
H: 0.53%
C: -3.07%
treatment report macular market
Macular Degeneration Treatment Market size worth $ 11.98 Billion, Globally, by 2028 at 6.01% CAGR: Verified Market Research®
Published: 2022-02-14 (Crawled : 09:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: -0.81%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.48%
H: 1.52%
C: -1.08%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.92%
H: 0.87%
C: -0.91%
research treatment macular
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-02-12 (Crawled : 20:20) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 treatment liver trial positive diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022
Published: 2022-02-09 (Crawled : 17:00) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 3.58%
H: 1.42%
C: 0.62%
rgx-111 treatment symposium trial positive mps-ih mps-i
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-11-22 (Crawled : 12:00) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 7.03%
H: 1.84%
C: -1.52%
treatment orphan drug muscular dystrophy duchenne gene therapy therapy drug granted designation
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
Published: 2021-10-09 (Crawled : 16:20) - prnewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
treatment positive retina liver trial diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: -1.5%
H: 0.0%
C: 0.0%
treatment positive retina liver trial
Dutch Biotech Acquires Corlieve to Develop Treatment for Temporal Lobe Epilepsy
Published: 2021-06-23 (Crawled : 17:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.52%
H: 1.49%
C: 0.5%
treatment biotech iot
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.